Advertisement
Research Article| Volume 171, ISSUE 2, P291-294, December 2013

A pilot study on the combined use of letrozole, mifepristone and misoprostol in termination of first trimester pregnancy up to 9 weeks’ gestation

  • Joyce Chai
    Correspondence
    Corresponding author at: Department of Obstetrics and Gynaecology, 6/F., Professorial Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong Special Administrative Region. Tel.: +852 22554518.
    Affiliations
    Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong Special Administrative Region
    Search for articles by this author
  • Pak-Chung Ho
    Affiliations
    Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong Special Administrative Region
    Search for articles by this author
Published:September 30, 2013DOI:https://doi.org/10.1016/j.ejogrb.2013.09.017

      Abstract

      Objective

      To assess the feasibility of adding letrozole to the standard regimen of mifepristone and misoprostol for termination of pregnancy up to 63 days.

      Study design

      We recruited 50 subjects who had requested legal termination of pregnancy up to 63 days. Medical abortion was performed with a singe dose of 200 mg mifepristone and 10 mg of letrozole daily for 3 days followed by 800 mcg vaginal misoprostol.

      Results

      The complete abortion rate was 98% (95% CI: 94–100%). The median induction-to-abortion interval of the regimen was 5.1 h (range 1.2–56 h). No serious adverse effects were reported.

      Conclusions

      The results of this pilot study suggest that a regimen of mifepristone, letrozole and misoprostol is associated with a high complete abortion rate without major adverse events.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • ACOG
        ACOG Practice Bulletin. Clinical management guidelines of obstetrician-gynecologists. Number 67, October 2005. Medical management of abortion.
        Obstet Gynecol. 2005; 106: 871-872
        • Royal College of Obstetricians and Gynaecologists
        The care of women requesting induced abortion. Evidence-based Clinical Guideline No. 7.
        RCOG Press, London (UK)2004
        • Baird D.T.
        Mode of action of medical methods of abortion.
        J Am Med Women's Assoc. 2000; 55: 121-126
        • Van Look P.F.A.
        • Bygdeman M.
        Antiprogesterone steroids: a new dimension in human fertility regulation.
        Oxford Rev Reprod Biol. 1989; 1: 1-60
        • Ashok P.W.
        • Penney G.C.
        • Flett G.M.
        • Templeton A.
        An effective regimen for early medical abortion: a report of 2000 consecutive cases.
        Hum Reprod. 1998; 13: 2962-2965
        • Schaff E.A.
        • Eisinger S.H.
        • Stadalius L.S.
        • Franks P.
        • Gore B.Z.
        • Poppema S.
        Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.
        Contraception. 1999; 59: 1-6
        • Albrecht E.D.
        • Aberdeen G.W.
        • Pepe G.J.
        The role of estrogen in the maintenance of primate pregnancy.
        Am J Obstet Gynecol. 2000; 182: 432-438
        • Bisagni G.
        • Cocconi G.
        • Scaglione F.
        • Fraschini F.
        • Pfister C.H.
        • Trunet P.F.
        Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study.
        Ann Oncol. 1996; 7: 99-102
        • Shi L.
        • Shi S.Q.
        • Given R.L.
        • Von Hertzen H.
        • Garfield R.E.
        Synergistic effects of antiprogestins and iNOS or aromatase inhibitors on establishment and maintenance of pregnancy.
        Steroids. 2003; 68: 1077-1084
        • Lee C.Y.V.
        • Ng E.H.Y.
        • Yeung W.S.B.
        • Ho P.C.
        Misoprostol with or without letrozole pretreatment for termination of pregnancy: a randomized controlled trial.
        Obstet Gynecol. 2011; 117: 317-323
        • Lee C.Y.V.
        • Tang O.S.
        • Ng H.Y.E.
        • Yeung S.B.W.
        • Ho P.C.
        A pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 days.
        Contraception. 2011; 83: 62-67
        • Yeung T.W.
        • Lee V.C.
        • Ng E.H.
        • Ho P.C.
        A pilot study on the use of a 7-day course of letrozole followed by misoprostol for the termination of early pregnancy up to 63 days.
        Contraception. 2012; 86: 763-769
        • von Hertzen H.
        • Huong N.T.
        • Piaggio G.
        • et al.
        Misoprostol dose and route after mifepristone for early medical abortion: a randomized controlled noninferiority trial.
        BJOG. 2010; 117: 1186-1196
        • Spitz I.M.
        • Bardin C.W.
        • Benton L.
        • et al.
        Early pregnancy termination with mifepristone and misoprostol in the United States.
        N Engl J Med. 1998; 338: 1241-1247
        • Schaff E.A.
        • Eisinger S.H.
        • Stadalius L.S.
        • et al.
        Low dose mifepristone 200 mg and vaginal misoprostol for abortion.
        Contraception. 1999; 59: 1-6
        • Kallner H.K.
        • Ho P.C.
        • Gemzell-Danielsson K.
        Effect of letrozole on uterine tonus and contractility: a randomized controlled trial.
        Contraception. 2012; 86: 419-424
        • Billiar R.B.
        • Pepe G.J.
        • Albrecht E.D.
        Immunocytochemical identification of the oestrogen receptor in the nuclei of cultured human placental syncytiotrophoblasts.
        Placenta. 1997; 18: 365-370
        • Rama S.
        • Peutrusz
        • Rao A.J.
        Hormonal regulation of human trophoblast differentiation: a possible role for 17-beta-estradiol and GnRH.
        Mol Cell Endocrinol. 2004; 218: 79-94
        • Albrecht E.
        • Robb V.A.
        • Pepe G.J.
        Regulation of placental vascular endothelial growth/permeability factor expression and angiogenesis by estrogen during early baboon pregnancy.
        J Clin Endocrinol Metab. 2004; 89: 5803-5809
        • Albrecht E.D.
        • Babischkin J.S.
        • Pepe G.J.
        Regulation of placental villous angiopoietin-1 and -2 expression by estrogen during baboon pregnancy.
        Mol Reprod Dev. 2008; 75: 504-511